跳至主要内容
临床试验/NCT04258930
NCT04258930Unknown不适用

Randomized Comparative Open Trial of Occlusive Therapy With a Hydrocolloid or Silicone Versus Conventional Drying Treatment for the Local Care of Acute Lesions Caused by Herpes Zoster.

Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.2 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2020年2月26日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
36
试验地点
2
主要终点
Change in pain score using the Zoster Brief Pain Inventory (ZBPI)

研究概览

简要总结

This study evaluates the addition of occlusive dressings (hydrocolloids) or topical silicone gel in the treatment of shingles (herpes zoster). One third of the participants will receive a hydrocolloid occlusive dressing, one third will receive the topical silicone gel and one third will receive the current treatment of the rash consisting of drying solutions (soaks).

详细描述

Herpes zoster (HZ), also known shingles, is a viral disease caused by the varicella-zoster virus. It is considered a local reactivation of varicella (chicken pox). The rash of herpes zoster is characterized by vesicles that appear following a single dermatome (the territory that is innervated by one spinal nerve). These vesicles may be very painful and cause discomfort due to draining and crusting. When a person becomes sick with shingles healthcare professionals prescribe systemic (oral) treatment with antivirals (e.g. acyclovir) and pain medication according to the type and severity. To treat the local lesions caused by shingles, over the centuries, patients have been treated with drying solutions and drying powders. This practice has been passed on through the years without any evidence supporting its effectiveness, in all likelihood due to the fact that the rash is self-limited to 2 to 3 weeks. Recently, new evidence has shown that the vesicles that appear with the shingles rash are not superficial but involve deeper areas of the skin and should be considered partial thickness wounds. Since 1962, it has become clear that partial thickness wounds benefit from occlusive therapy (keeping wounds closed and avoiding drying) such as dressings and occlusive gels that keep the wound wet rather than allowing it to dry.

In this clinical trial the investigators believe that given this information, using occlusive therapy with a hydrocolloid dressing or a silicone-based gel may heal the rash of herpes zoster, decrease pain and improve the quality of life, much faster than the treatment currently used of drying the area with powders and solutions.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with clinical diagnosis of HZ confirmed by a certified dermatologist
  • Patients having maximum 72 hours from the start of the first vesicle
  • Older than 18 years

排除标准

  • Patients with dimethicone allergy
  • Patients with hydrocolloid allergy
  • Patients with acetaminophen allergy
  • Patients with aluminium sulphate and calcium acetate allergy
  • Patients with acyclovir allergy
  • Pregnant women
  • Breastfeeding women
  • Unable to give informed consent
  • Patients with signs of infection over the skin rash
  • Patients with disseminated HZ
  • Patients with hemorrhagic HZ
  • Patients with complications such as pneumonia or encephalitis
  • Patients unable to apply the treatment to the affected area
  • Patients with HZ-associated keratitis
  • Patients whose rash is located to hairy areas that may hinder occlusion with the hydrocolloid dressing.

结局指标

主要结局

Change in pain score using the Zoster Brief Pain Inventory (ZBPI)

时间窗: Evaluation at baseline, 5 days, 10 days and 40 days.

Score reduction in the Zoster Brief Pain Inventory (ZBPI). It uses an 11-point Likert scale (0-10) to rate herpes zoster pain and discomfort for four different dimensions (worst, least, and average during the past 24 hours, and now) and herpes zoster pain and discomfort-related interference with seven items of activities of daily living and health: general activity, mood, walking ability, work, relations with others, sleep, enjoyment of life.

Number of days to achieve complete healing of cutaneous lesions.

时间窗: Evaluation at 10 days.

The total number of days from the beginning of the rash to the disappearance of all scabs.

Pain reduction as per acetaminophen need

时间窗: Evaluation at 40 days.

Amount of acetaminophen taken in total for pain control through the duration of the trial.

Change in the quality of life score as measured by the Dermatology Life Quality Index (DLQI)

时间窗: Evaluation at baseline, 5 days, 10 days and 40 days.

Quality of life score improvement as measured by the Dermatology Life Quality Index (DLQI). There are 10 questions, covering the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, treatment. Each question refers to the impact of the skin disease on the patient's life over the previous week. Each question is scored from 0 to 3, giving a possible score range form 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life).

次要结局

  • Description and quantification of any side effect during the trial.(Evaluation at baseline, 5 days, 10 days and 40 days.)

研究者

发起方
Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Occlusion vs Standard Treatment for the Treatment of... | 临床试验